SpliSense Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $13M

  • Investors
  • 5

SpliSense General Information

Description

Developer of a novel drug designed to heal splicing mutations in genetic diseases. The company's drug candidates are based on antisense oligonucleotides, focusing on mutations in the CFTR gene, enabling medical practitioners to effectively treat cystic fibrosis.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Biohouse Labs, Minrav Building 1st Floor
  • Haddasah Ein Karem
  • Jerusalem 9112101
  • Israel
+972
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Biohouse Labs, Minrav Building 1st Floor
  • Haddasah Ein Karem
  • Jerusalem 9112101
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SpliSense Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 16-Jun-2026 $13M Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 13-May-2021 Completed Clinical Trials - Phase 2
4. Seed Round 01-Feb-2020 Completed Pre-Clinical Trials
3. Seed Round 01-Nov-2018 Completed Pre-Clinical Trials
2. Grant 01-Jan-2017 $400K Completed Startup
1. Accelerator/Incubator Completed Startup
To view SpliSense’s complete valuation and funding history, request access »

SpliSense Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred B2
Preferred B1
Preferred A 2,000,000 $null $3.03 $3.03 1x $3.03 15.66%
To view SpliSense’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

SpliSense Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a novel drug designed to heal splicing mutations in genetic diseases. The company's drug candidates are bas
Drug Discovery
Jerusalem, Israel
17 As of 2026

Novato, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SpliSense Competitors (1)

One of SpliSense’s competitors is Ultragenyx Pharmaceutical, a Formerly VC-backed company based in Novato, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ultragenyx Pharmaceutical Formerly VC-backed Novato, CA
You’re viewing 1 of 1 competitors. Get the full list »

SpliSense Patents

SpliSense Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025052391-A1 Antisense oligonucleotides targeting the cftr 3849+10 kilobase (kb) c->t splicing mutation Inactive 06-Sep-2023
CA-3238565-A1 Muc5-targeted antisense oligonucleotides and related methods for modulating expression of muc5ac and muc5b Pending 09-Dec-2021
EP-4426840-A1 Muc5-targeted antisense oligonucleotides and related methods for modulating expression of muc5ac and muc5b Pending 09-Dec-2021
EP-4426840-A4 Muc5-targeted antisense oligonucleotides and related methods for modulating expression of muc5ac and muc5b Pending 09-Dec-2021
WO-2023105527-A1 Muc5-targeted antisense oligonucleotides and related methods for modulating expression of muc5ac and muc5b Inactive 09-Dec-2021 C12N15/113
To view SpliSense’s complete patent history, request access »

SpliSense Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SpliSense Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Biotel Limited Corporation Minority
Israel Biotech Fund Venture Capital Minority
OrbiMed Growth/Expansion Minority
Integra Holdings Venture Capital Minority
Cystic Fibrosis Foundation Limited Partner Minority
To view SpliSense’s complete investors history, request access »

SpliSense FAQs

  • When was SpliSense founded?

    SpliSense was founded in 2016.

  • Where is SpliSense headquartered?

    SpliSense is headquartered in Jerusalem, Israel.

  • What is the size of SpliSense?

    SpliSense has 17 total employees.

  • What industry is SpliSense in?

    SpliSense’s primary industry is Drug Discovery.

  • Is SpliSense a private or public company?

    SpliSense is a Private company.

  • What is SpliSense’s current revenue?

    The current revenue for SpliSense is .

  • How much funding has SpliSense raised over time?

    SpliSense has raised $56M.

  • Who are SpliSense’s investors?

    Biotel Limited, Israel Biotech Fund, OrbiMed, Integra Holdings, and Cystic Fibrosis Foundation have invested in SpliSense.

  • Who are SpliSense’s competitors?

    Ultragenyx Pharmaceutical is a competitor of SpliSense.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process